427 related articles for article (PubMed ID: 30785241)
1. [Selection of the optimal device-aided therapy in Parkinson's disease].
Kovács N; Aschermann Z; Juhász A; Harmat M; Pintér D; Janszky J
Ideggyogy Sz; 2019 Jan; 72(1-2):5-11. PubMed ID: 30785241
[TBL] [Abstract][Full Text] [Related]
2. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Wirdefeldt K; Odin P; Nyholm D
CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
5. Use of advanced therapies for Parkinson's disease in Norway.
Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
[TBL] [Abstract][Full Text] [Related]
6. [Treatment possibilities in advanced Parkinson's disease].
Takáts A; Nagy H; Radics P; Tóth A; Tamás G
Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
[TBL] [Abstract][Full Text] [Related]
7. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
[TBL] [Abstract][Full Text] [Related]
8. Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
Elkouzi A; Ramirez-Zamora A; Zeilman P; Barabas M; Eisinger RS; Malaty IA; Okun MS; Almeida L
Ann Clin Transl Neurol; 2019 Oct; 6(10):1989-1995. PubMed ID: 31518070
[TBL] [Abstract][Full Text] [Related]
9. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
[TBL] [Abstract][Full Text] [Related]
10. Advanced therapies in Parkinson's disease: Long-term retrospective study.
Merola A; Espay AJ; Romagnolo A; Bernardini A; Rizzi L; Rosso M; Espay KJ; Zibetti M; Lanotte M; Lopiano L
Parkinsonism Relat Disord; 2016 Aug; 29():104-8. PubMed ID: 27215392
[TBL] [Abstract][Full Text] [Related]
11. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
[TBL] [Abstract][Full Text] [Related]
12. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
[TBL] [Abstract][Full Text] [Related]
13. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
[TBL] [Abstract][Full Text] [Related]
14. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of levodopa treatment in advanced Parkinson's disease in the experiences of the neurology clinics of Târgu Mureș, Romania].
Szász JA; Szatmári S; Constantin V; Mihály I; Rácz A; Domokos LC; Vajda T; Orbán-Kis K
Orv Hetil; 2019 Apr; 160(17):662-669. PubMed ID: 31010306
[TBL] [Abstract][Full Text] [Related]
16. The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review.
Zhang XR; Jiang ZY; Zhang ZR; Chen HJ; Wu K; He JC; Xie CL
Drug Des Devel Ther; 2020; 14():845-854. PubMed ID: 32161444
[TBL] [Abstract][Full Text] [Related]
17. [Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
Nagy H; Takáts A; Tóth A; Bereczki D; Klivényi P; Dézsi L; Dibó G; Vécsei L; Kovács N; Aschermann Z; Komoly S; Varannai L; Zemlényi G; Valikovics A
Ideggyogy Sz; 2014 Nov; 67(11-12):385-9. PubMed ID: 25720240
[TBL] [Abstract][Full Text] [Related]
18. [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
Titova NV; Katunina EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):94-100. PubMed ID: 26171484
[TBL] [Abstract][Full Text] [Related]
19. Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
Sahlström T; Eklund M; Timpka J; Henriksen T; Nyholm D; Odin P
Acta Neurol Scand; 2018 Jul; 138(1):78-84. PubMed ID: 29569237
[TBL] [Abstract][Full Text] [Related]
20. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
Ray Chaudhuri K; Antonini A; Robieson WZ; Sanchez-Soliño O; Bergmann L; Poewe W;
Eur J Neurol; 2019 Apr; 26(4):581-e43. PubMed ID: 30353942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
